EGFR and lung carcinoma: Although third-generation EGFR-TKIs, such as Osimertinib, have provided effective treatment options for patients with the T790M mutation, resistance inevitably occurs after treatment with these agents, limiting the long-term survival of patients with advanced EGFR-mutated lung cancer [29].